Kaïs Aldabbagh

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 164 citations · Full text

Medicine, Infectious Diseases, Oncology +14

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE

Juliette Thariat, Thomas Schouman, A. Brouchet et al. · Annals of Oncology · 2012 · 56 citations · Full text

Medicine, Oncology, Surgery +15

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability

Olivier Bouché, Thierry André, Karine Le Malicot et al. · JAMA Oncology · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD

Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière et al. · Annals of Oncology · 2023 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17

TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière et al. · The Lancet Oncology · 2025 · 22 citations

Medicine, Oncology, Chemotherapy +5